“We believe a national RSV program is needed so all infants born in Australia have access to Beyfortus. A national program for next year’s RSV season will make it easier for parents and healthcare professionals to discuss infant eligibility, no matter where the child is born," said Regis Launay, the general manager of vaccines for Sanofi Australia and New Zealand.
More states announce RSV programs as families call for national action
March 26, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
It is profoundly wrong for any system to exclude compassion while outsourcing it to others
March 16, 2026 - - Latest News -
Scientists identify highly specific targets that could transform multiple myeloma treatment
March 15, 2026 - - Australian Biotech -
CSL Seqirus' adjuvanted flu vaccine approval extended to Australians aged 50 and over
March 15, 2026 - - Latest News -
GSK claims Pharma Cup as Kosi Challenge surpasses fundraising record
March 15, 2026 - - Latest News -
New program aims to make women’s health care more affordable and accessible
March 13, 2026 - - Latest News -
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News

